CD274 and non-small cell lung carcinoma: The phase Ib experience with the combination of durvalumab, an IgG1 antagonist antibody that binds PD-L1 and inhibits its function, with tremelimumab, a fully human IgG2 isotype that inhibits the CTLA-4 receptor, in NSCLC has recently been published (41).